ArticleJournal of gastrointestinal cancer2026
Cannabis Use Disorder and Risk of Pancreatic Cancer in Patients with Chronic Pancreatitis: a Multicenter Retrospective Cohort Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Authors' Response: Cannabis Use Disorder and Risk of Pancreatic Cancer in Patients with Chronic Pancreatitis: a Multicenter Retrospective Cohort Study.Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabis use is increasing globally, with a parallel rise in Cannabis Use Disorder (CUD). Chronic pancreatitis (CP), a progressive inflammatory condition, is associated with acute pancreatitis (AP) flares and an elevated risk of pancreatic cancer (PC). Although cannabis is often used for pain management in CP, its impact on PC risk and AP flare frequency is unclear.
methodsWe conducted a retrospective cohort study using TriNetX to identify adults with CP, stratified by CUD status. Patients with pre-existing PC were excluded. Propensity score matching (1:1) was applied for demographics, behavioral factors, and comorbidities. The primary outcome was PC incidence; the secondary was AP flare frequency. Hazard ratios (HR) were calculated using Cox proportional hazards regression. Sensitivity analysis adjusted for opioid use disorder.
resultsBefore matching, the CUD cohort (n = 10,864) had higher rates of alcohol and nicotine use than controls (n = 42,160). After matching, 6,858 patients per group remained with balanced covariates (SMD < 0.1). Mean follow-up was shorter in the CUD cohort (736 ± 422 vs. 896 ± 368 days). CUD was associated with a significantly reduced risk of PC (67 vs. 274 cases; HR: 0.263, 95% CI: 0.202-0.344; p < 0.001) but a modest increase in AP flare risk (HR: 1.102, 95% CI: 1.043-1.166; p = 0.001). Results were consistent in the sensitivity analysis.
conclusionsAmong patients with CP, CUD was associated with lower rates of PC detection during available follow-up, but a slightly increased risk of AP flares. These findings warrant further prospective and mechanistic studies to clarify cannabis's role in pancreatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.